-
1 Comment
Bioton S.A. is currently in a long term uptrend where the price is trading 4.9% above its 200 day moving average.
Bioton S.A.'s total revenue sank by 70.6% to $43M since the same quarter in the previous year.
Its net income has increased by 102.7% to $2M since the same quarter in the previous year.
Finally, its free cash flow grew by 534.7% to $25M since the same quarter in the previous year.
Based on the above factors, Bioton S.A. gets an overall score of 3/5.
| ISIN | PLBIOTN00029 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | WAR |
| CurrencyCode | PLN |
| Dividend Yield | None |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.32 |
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BIO.WAR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
